- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06319027
Identificando descobertas em exames cerebrais que poderiam ajudar a fazer melhores previsões sobre a progressão do câncer cerebral, o estudo GABLE (GABLE)
Ensaio de ambiente de aprendizagem de biomarcadores acelerados de glioblastoma de fase II (GABLE)
This phase II trial studies whether different imaging techniques can provide additional and more accurate information than the usual approach for assessing the activity of tumors in patients with newly diagnosed glioblastoma. The usual approach for this currently is magnetic resonance imaging (MRI). This study is trying to learn more about the meaning of changes in MRI scans after treatment, as while the appearance of some of these changes may reflect progressing tumor, some may be due the treatment. Dynamic susceptibility contrast (DSC)-MRIs, along with positron emission tomography (PET) and/or magnetic resonance (MR) spectroscopy, may help doctors tell which changes are a reflection of the treatment and which changes may be due to progressing tumor.
Visão geral do estudo
Status
Condições
Descrição detalhada
PRIMARY OBJECTIVE:
I. For each biomarker (dynamic susceptibility contrast-enhanced MR Imaging, fluciclovine F18 [18F-fluciclovine] PET, MR spectroscopy), to evaluate whether the biomarker can stratify patients with newly diagnosed glioblastoma (GBM) that have progressive enhancement within 12 weeks post-radiation therapy (XRT) into risk groups based on overall survival.
SECONDARY OBJECTIVES:
I. To evaluate whether each biomarker (dynamic susceptibility contrast-enhanced MR Imaging, 18F-fluciclovine PET, MR spectroscopy) can predict final determination of pseudo-progression (PsP) versus (vs.) true progression on follow-up MR imaging as evaluated by a semi-automated central reading process and by institutional radiologist readings.
II. To evaluate whether a prediction model that incorporates multiple biomarkers can discriminate patients with progressive enhancement within 12 weeks post-XRT into high and low risk groups for overall survival.
III. To evaluate whether clinical and imaging biomarkers are predictive of overall and progression-free survival in patients who do not show progressive enhancement within 12 weeks post-XRT.
EXPLORATORY OBJECTIVE:
I. To determine how different methods of defining PsP vs. true progression on imaging relate to patient survival.
OUTLINE:
Patients receive a gadolinium-based contrast agent and undergo DSC-MRI scans at 4 and 8 weeks after completion of standard of care (SOC) radiation therapy. Patients with evidence of disease progression then undergo MR spectroscopy or receive fluciclovine F18 intravenously (IV) and undergo PET scan within 12 weeks of SOC radiation therapy completion.
After completion of study intervention, patients are followed up every 8 weeks for 1 year followed by every 12 weeks for 5 years.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35233
- Recrutamento
- University of Alabama at Birmingham Cancer Center
-
Contato:
- Site Public Contact
- E-mail: gingerreeves@uabmc.edu
-
Investigador principal:
- Jonathan E. McConathy
-
-
California
-
Los Angeles, California, Estados Unidos, 90048
- Recrutamento
- Cedars-Sinai Medical Center
-
Investigador principal:
- Jeremy D. Rudnick
-
Contato:
- Site Public Contact
- Número de telefone: 310-423-2133
- E-mail: Cancer.trial.info@cshs.org
-
-
Florida
-
Jacksonville, Florida, Estados Unidos, 32207
- Recrutamento
- Baptist MD Anderson Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 904-202-7468
-
Investigador principal:
- Robert Cavaliere
-
Tampa, Florida, Estados Unidos, 33612
- Recrutamento
- Moffitt Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 800-679-0775
- E-mail: ClinicalTrials@moffitt.org
-
Investigador principal:
- Joaquim Farinhas
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Recrutamento
- Emory University Hospital/Winship Cancer Institute
-
Contato:
- Site Public Contact
- Número de telefone: 404-778-1868
-
Investigador principal:
- Hui-Kuo G. Shu
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109
- Recrutamento
- University of Michigan Rogel Cancer Center
-
Investigador principal:
- Michelle M. Kim
-
Contato:
- Site Public Contact
- Número de telefone: 800-865-1125
- E-mail: CancerAnswerLine@med.umich.edu
-
-
North Carolina
-
Charlotte, North Carolina, Estados Unidos, 28203
- Suspenso
- Carolinas Medical Center/Levine Cancer Institute
-
Durham, North Carolina, Estados Unidos, 27710
- Recrutamento
- Duke University Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 888-275-3853
-
Investigador principal:
- Annick Desjardins
-
Winston-Salem, North Carolina, Estados Unidos, 27157
- Recrutamento
- Wake Forest University Health Sciences
-
Contato:
- Site Public Contact
- Número de telefone: 336-713-6771
-
Investigador principal:
- Marc Benayoun
-
-
Rhode Island
-
Providence, Rhode Island, Estados Unidos, 02903
- Suspenso
- Rhode Island Hospital
-
-
West Virginia
-
Huntington, West Virginia, Estados Unidos, 25701
- Recrutamento
- Edwards Comprehensive Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 304-399-6566
- E-mail: Christina.Cole@chhi.org
-
Investigador principal:
- Toni O. Pacioles
-
Morgantown, West Virginia, Estados Unidos, 26506
- Recrutamento
- West Virginia University Healthcare
-
Contato:
- Site Public Contact
- Número de telefone: 304-293-7374
- E-mail: cancertrialsinfo@hsc.wvu.edu
-
Investigador principal:
- Sonikpreet Aulakh
-
-
Wisconsin
-
Madison, Wisconsin, Estados Unidos, 53792
- Recrutamento
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 800-622-8922
- E-mail: clinicaltrials@cancer.wisc.edu
-
Investigador principal:
- Michael Veronesi
-
Madison, Wisconsin, Estados Unidos, 53718
- Recrutamento
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 800-622-8922
- E-mail: clinicaltrials@cancer.wisc.edu
-
Investigador principal:
- Michael Veronesi
-
Menomonee Falls, Wisconsin, Estados Unidos, 53051
- Recrutamento
- Froedtert Menomonee Falls Hospital
-
Investigador principal:
- Jennifer M. Connelly
-
Contato:
- Site Public Contact
- Número de telefone: 262-257-5100
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- Recrutamento
- Medical College of Wisconsin
-
Investigador principal:
- Jennifer M. Connelly
-
Contato:
- Site Public Contact
- Número de telefone: 414-805-3666
-
Oak Creek, Wisconsin, Estados Unidos, 53154
- Recrutamento
- Drexel Town Square Health Center
-
Investigador principal:
- Jennifer M. Connelly
-
Contato:
- Site Public Contact
- Número de telefone: 414-805-0505
-
West Bend, Wisconsin, Estados Unidos, 53095
- Recrutamento
- Froedtert West Bend Hospital/Kraemer Cancer Center
-
Investigador principal:
- Jennifer M. Connelly
-
Contato:
- Site Public Contact
- Número de telefone: 414-805-0505
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Patient must be ≥ 18 years of age.
-
Patient must have a Karnofsky Performance Status ≥ 60%.
-
Patient must have newly diagnosed GBM (must be IDH wild type), with pathologic proof, based on World Health Organization (WHO) 2021 criteria.
-
Patient must be planning to receive standard-of-care treatment for newly diagnosed glioblastoma.
-
Patient must have completed an MRI prior to the diagnostic surgery for GBM and have images available for upload into Transfer of Images and Data (TRIAD).
-
Patient must have diagnostic surgery for GBM within 7 weeks prior to registration.
-
Patient must have O6-Methylguanine-DNA Methyltransferase (MGMT) methylation status ordered at time of registration.
-
Patient must have a post-operative (op) MRI completed within 3 weeks after diagnostic surgery for GBM and have images available for upload into TRIAD.
-
Patient must have no contraindications to MRI, including injection of gadolinium-based contrast agents, and demonstrated ability to tolerate MRI on pre-surgical imaging.
-
Patient must have no allergies to agents that may potentially be used for non-standard of care imaging (18F-fluciclovine, MR contrast).
-
Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the interventions being used.
- All patients of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy.
- A patient of childbearing potential is defined as anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
-
Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible.
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Diagnóstico
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Diagnostic (DSC-MRI, fluciclovine F18 PET, MR spectroscopy)
Patients receive a gadolinium-based contrast agent and undergo DSC-MRI scans at 4 and 8 weeks after completion of SOC radiation therapy. Patients with evidence of disease progression then undergo MR spectroscopy or receive fluciclovine F18 IV and undergo PET scan within 12 weeks of SOC radiation therapy completion. |
Undergo PET scan
Outros nomes:
Given IV
Outros nomes:
Undergo DSC-MRI
Outros nomes:
Receive gadolinium-based contrast agent
Outros nomes:
Undergo MR spectroscopy
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Overall survival (OS)
Prazo: From biomarker collection to death due to any cause, assessed up to 6 years
|
Will use a two-sided log-rank test to compare the difference in OS between marker positive and marker negative participants using a significance level of 0.05. |
From biomarker collection to death due to any cause, assessed up to 6 years
|
|
Event free survival (EFS)
Prazo: From biomarker collection until progression by Neurological Assessment in Neuro-Oncology (NANO) criteria or death, assessed up to 6 years
|
NANO progression is defined as a ≥ 2 level worsening from baseline or best level of function in at least one domain or worsening to the highest score within ≥1 domain that is felt to be related to underlying tumor progression and not attributable to a comorbid event or change in concurrent medication. Will be based on the conditional power of a two-sided log-rank test for EFS between marker positive and marker negative participants using a significance level of 0.05. |
From biomarker collection until progression by Neurological Assessment in Neuro-Oncology (NANO) criteria or death, assessed up to 6 years
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Sobrevivência livre de progressão (PFS)
Prazo: Da cirurgia até o início da progressão ou morte por qualquer causa, avaliada em até 6 anos
|
Da cirurgia até o início da progressão ou morte por qualquer causa, avaliada em até 6 anos
|
|
|
True disease progression and pseudo-progression (PsP)
Prazo: Within 12 weeks post radiation therapy (XRT)
|
The T3 MRI will be used to determine whether progressive enhancement seen within 12 weeks post-XRT was true progression or PsP. |
Within 12 weeks post radiation therapy (XRT)
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Daniel P Barboriak, ECOG-ACRIN Cancer Research Group
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Neoplasias
- Neoplasias por Tipo Histológico
- Neoplasias Glandulares e Epiteliais
- Astrocitoma
- Glioma
- Neoplasias Neuroepiteliais
- Tumores Neuroectodérmicos
- Neoplasias, Células Germinativas e Embrionárias
- Neoplasias, Tecido Nervoso
- Glioblastoma
- Técnicas de investigação
- Técnicas de química, analíticas
- Análise de espectro
- Espectroscopia de ressonância magnética
- Fluciclovina F-18
Outros números de identificação do estudo
- EAF223
- U10CA180820 (Concessão/Contrato do NIH dos EUA)
- EAF223 (Outro identificador: CTEP)
- NCI-2023-08557 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- EAF223 (Outro identificador: ECOG-ACRIN Cancer Research Group)
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .